Author_Year,Country,Study_Design,Intervention_Denosumab,Control_N,Age>18,OP_only,Route_SC_only,Control_Group_None,Sample_N>100,Invasive_Procedure_Documented,FollowUp>6m,MRONJ_Incidence_Reported,Latency_Documented,Eligibility,Reason_for_Exclusion
Everts-Graber 2022,Switzerland,Retrospective registry cohort,3068 pts /4236 patient-years,None (vs BP only),Yes,Yes,Yes,Yes (so fails),Yes,"No (general ONJ, triggers varied)",Yes,Yes (12 cases),No,Exclude,No anti-resorptive-free control; MRONJ not limited to post-procedure
Wei 2025,Taiwan,Retrospective cohort of dental extractions,276 pts /376 extractions,None,Yes,Yes,Yes,Yes,Yes,Yes (tooth extractions),Yes,Yes (21 cases),Drug duration & interruption but not procedure?’ONJ,Exclude,No medication-naive control
Kwack & Park 2023,Korea,Retrospective prediction - Model dataset,Subset of 340 pts,None,Yes,Yes,Yes,Yes,Yes,Yes (extraction / implant),Yes,Yes (overall 130 cases),No,Exclude,No medication-naive control; mixed AR classes
Watts 2019,Multinational,Extension of RCT (open-label denosumab),"4550 pts, 7 yrs exposure",Placebo only first 3y (no OPE data),Yes,Yes (post-menopause women),Yes,Yes (during OL),Yes,Yes (OPE survey),Yes (10yr),Yes (13 cases),Partial (time inciting event-> ONJ),Exclude,No concurrent medication-naive control group
